G roup A rotaviruses (RVs) remain the major cause of morbidity and mortality globally and are associated with an estimated 453,000 deaths (range 420,000-494,000 deaths) annually in infants and young children <5 years of age, 1 and approximately 85% of these deaths occurring in Sub-Saharan Africa. 1, 2 Infants and young children <2 years of age are most vulnerable to RV infection that often results in severe diarrhea and dehydration, causing hospitalization which can result in death. 3 This age group has been the primary target of protection with RV vaccines, and large-scale efficacy and safety trials of 2 RV vaccines, Rotarix (GlaxoSmithKline, Rixensart, Belgium), containing a single human G1P [8] RV strain, and RotaTeq (Merck & Co., Whitehouse Station, NJ), containing 5 bovine-human reassortant RV strains expressing 5 human serotypes (G1, G2, G3, G4 and P [8] ) have demonstrated the impact of these vaccines in developing countries. [4] [5] [6] [7] [8] The recent clinical trials in Africa and Asia [7] [8] [9] found that the vaccine significantly reduces severe diarrhea episodes due to RV by 48-64% during the first year of life. These vaccines have been reported to induce significant protection against severe diarrhea caused by homotypic and heterotypic RV strains 4, 5, 10, 11 and reduce childhood deaths.
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The Rotarix and RotaTeq RV vaccines have proved to have high efficacy in developed countries. 4, 6, 13 Available since 2006, these vaccines have been licensed in many countries including Kenya. 14, 15 The recommendation by World Health Organization (WHO) that RV vaccines be included in all national immunization programs, particularly in those countries where diarrheal deaths account for >10% of <5 mortality, 16 has resulted in many countries applying for financial support from Global Alliance for Vaccines and Immunization to enable introduction of these vaccines. Based on WHO recommendations, Global Alliance for Vaccines and Immunization and other international partners have agreed to provide financial support for RV immunization in the developing world and the WHO Regional Office for Africa has been spearheading the sentinel surveillance of RV for the last 6 years. 15 The main aim of the ongoing RV hospitalbased surveillance studies being conducted in Africa and coordinated by the Regional Office for Africa of WHO is to monitor the burden of RV infection, prevalence of predominant genotypes and identify unusual and emerging strains in the continent. 15 Such studies are particularly important in countries such as Kenya that are considering introducing the RV vaccine in the expanded program for immunization.
RV is a non-enveloped virus with a triple-layered capsid containing 11 double-stranded RNA segments surrounded by 3 concentric protein layers. The outer capsid consists of VP7 (a glycoprotein) and VP4 (a protease-sensitive protein) which carry independent neutralization and protective antigens. 17 A binary system of RV classification has been established to designate the neutralization specificity of the VP7 and VP4 proteins. The VP7 genotype is known as G and the VP4 genotype as P. 17 To date, 27 different G and 35 P genotypes have been described in both humans and animals. 18 Globally, human infections have been mainly caused by 5 G types (G1-G4 and G9) and 3 P types (P [4] , P [6] and P [8] 15, [21] [22] [23] [24] Before the introduction and implementation of a universal RV vaccination program, continued monitoring of RV strain variations is important so that the impact of vaccination and any subsequent changes in circulating strains can be determined.
The main aim of this study was to determine the distribution of circulating G and P genotype among children <5 years of age admitted to hospitals with acute gastroenteritis in the eastern region of Kenya before RV vaccination introduction.
MATERIAL AND METHODS

Study Design
This study was a prospective hospital-based surveillance study in the eastern region of Kenya. The study was carried out in Meru General Hospital and Maua Methodist Hospital in Meru County. These hospitals are in close vicinity approximately 50 km apart and they both serve the same catchment area.
Collection of Stool Specimens
During September 2009 to August 2011, 500 fecal samples were collected from children <5 years of age admitted with acute diarrhea in Meru General Hospital and Maua Methodist Hospital in the eastern region of Kenya. These hospitals were selected based on the earlier study by Kiulia et al (2006) 21 and fulfilled requirements for RV surveillance study as outlined by WHO. 15, 25 Fecal samples and epidemiological data were collected from all children <5 years of age with severe nonbloody diarrhea admitted to the pediatrics ward and/or who visited the emergency department for treatment for acute gastroenteritis during the study period. A case of acute gastroenteritis was defined as the passage of ≥3 looser than normal stools within a 24-hour period or ≥2 episodes of vomiting unexplained by other reason and as described by the guardian or mother at presentation to the hospital.
RV Detection
A 10% suspension of fresh stool in sample diluent was made and tested for the presence of group A RV antigen using a commercial RV antigen detection enzyme immunoassay (ProSpecT Rotavirus test, Oxoid, Ely, United Kingdom) according to the manufacturer's instructions.
Viral RNA Extraction for Reverse Transcriptase Polymerase Chain Reaction
RV dsRNA was extracted using the QIAamp Viral RNA kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions, with slight modification. Briefly, a 10 % stool suspension was made in phosphate-buffered saline solution. The suspension was votexed, spinned down and supernatant used for RNA extraction. Purified extract was aliquoted and stored at −20°C until use.
VP7 and VP4 Genotyping of RV Strains
The VP7 and VP4 reverse transcriptase polymerase chain reaction (RT-PCR) amplification and genotyping were carried out as described elsewhere. 
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RESULTS
Prevalence of RV in Eastern Region
A total of 500 children with diarrhea were enrolled in the study with 189 (38%) found to be positive for RV infection by enzyme immunoassay.
Distribution of Circulating G and P Genotypes
Of the 189 enzyme immunoassay positive samples, 157 were randomly selected for further characterization by RT-PCR and they were representative of samples collected during the study period. Both G and P types were detected in 137/157 (87.3%) samples, while 7/157 (4.5%) samples remained nontypeable for both G and P types (Table 1) .
During the study period, the following G types were detected: G9 (50.9%), G1 (26.8%), G8 (12.1%), G12 (3.1%) and G2 (0.6%). Mixed G types were also detected in 2 (1.3%) samples, and no G types were obtained in 8 samples (5.1%). The following P types were detected: P [8] Table 1 ). Genotypes G3 and G4 were not detected in any of the samples analyzed during the study. The mixed G types detected were mostly G9/G12 and mixed P types were P[8] +P [4] and P [8] +P [6] (Table 1) .
In this study, genotype G9 predominated throughout the entire period (Table 1) The age distribution of patients to the RV genotypes circulating in the eastern region of Kenya is shown in Table 2 . RV infection was found in all the age groups at different frequencies. Among the globally common strains, G9P [8] and G8P [4] was found circulating in all age groups except in older children >25 months of age, whereas G1P [8] and G2P [4] were identified in younger children (7-12 months of age). G12P [6] were found circulating among children <24 months of age. Unusual strains and mixed infections were also found circulating in different age groups although at lower levels.
DISCUSSION
This study was performed to provide data on the circulating RV genotypes in the eastern region of Kenya, in anticipation of possible introduction of RV vaccine in the expanded program for immunization in Kenya. Human group A RV was detected in 37.8% of children hospitalized with acute gastroenteritis. This prevalence is within the range (6-56%) previously detected in Kenya 15, 22 and higher than the previous study which was carried out in the same region. 21 The detection rate of RV in this rural setting is similar to that previously reported in an urban setting in 2010.
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G9 genotype was the most common genotype, followed by G1 and then G8 which is uncommon globally, but detected in consistently in African countries. 15 The globally common genotype G2 was detected at lower levels in this study. This trend of G2 has also been documented in a study from 2002 to 2004 in the coastal region of Kenya 24 and in another study that was done during 2000-2002 where G2 strains were detected in about 12% of samples. 30 Over the last 8 years, no G2 has been documented in Kenya. The prevalence of G9 genotype was higher than that reported in the urban hospital setting in Kenya (50.9% vs. 8%), while the prevalence of the G8 genotype was slightly lower (12.1% vs. 20%) than that reported in the same urban setting. 5 In addition, mixed infections and nontypeable samples were substantially lower in the eastern region compared with previous studies (mixed infection with G type, 1.3% vs. 8% and G nontypeable 5.1 % vs. 28%). 15, 21 Genotype G9 has been dominant over most periods in the eastern region. 21 Genotype G8 is increasingly becoming 1 of the dominant genotypes and genotype G1 had shown an increase in this region of Kenya over the last 2 years. Conversely, genotype G3 and G4 that were dominant in the 1990s were not detected in this study. 22 Recently, G12 genotypes have been increasingly detected in various countries, including in Africa, 31, 32 but have not previously been reported from Kenya.
15 G12 genotypes were confirmed in 3.1% of samples by sequence analysis in the current study (data not shown).
Continuous monitoring of circulating genotypes in Kenya is important, because the frequency of the genotypes could change over time. Seasonal shifts of RV strains in a given geographical region have been observed in many countries, [33] [34] [35] [36] and it is a possible mechanism that the virus can use to evade herd immunity and ultimately persist in that human population. 37 Notably, this was described for G2P [4] strain in South Africa. 38 The diversity of genotypes as found in this study may be explained by the active interaction of people in the region, poor environmental conditions and close contact with domesticated animals.
Despite the substantial strain heterogeneity detected in this study, RV vaccines have been shown to provide heterotypic protection against a wide range of circulating strains. For example, in the Rotarix clinical trials in Africa, the vaccine, which is based on an attenuated G1P [8] human RV strain, provided similar protection against G1 strains (64%) and non-G1 strains (60%). 8, 11 However, further study on strain-specific vaccine effectiveness in settings like Kenya is still needed to monitor the impact of vaccines on the long-term epidemiology of strains in circulation. Continued monitoring of RV genotype distribution will be valuable to document the diversity and changes in the circulating strains that may be more important than ever following the introduction of RV vaccination Our study had some limitations; for instance, the data collected were from one regional in the eastern Kenya and may not generally represent the actual burden of the disease and RV strains circulating in the entire country or even the eastern region. However, this study builds on the data generated in previous surveillance studies from this region using the same methodology and allows a temporal trend of circulating strains to be examined. The other limitation was that only a proportion of the RV-positive samples (157 of 189) were genotyped, although they were a representative of samples collected during the study period.
In conclusion, the present study confirms the current burden of RV gastroenteritis in younger children and also demonstrated a high prevalence of G9, G1 and G8 strains and the absence of 
